Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind placebo-controlled study of salfaprodil injection added to intravenous thrombolysis for acute ischemic stroke within 8 hours of onset
CTR20202064Phase 3Active
- Sponsor
- Zhejiang Apeloa Medical Technology
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of salfaprodil in ischemic stroke, sponsored by Zhejiang Apeloa Medical Technology. Started Dec 2020; status: active.
02
Drugs
salfaprodil
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20202064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202064.